Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 58.70K | 115.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 58.70K | 115.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.20M | 2.59M | 1.99M | 2.12M | 2.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -70.80K | -52.50K | -34.20K | -55.80K | -77.40K |
| Total Operating Expenses | 6.85M | 5.38M | 3.92M | 3.79M | 3.66M |
| Operating Income | -6.85M | -5.38M | -3.92M | -3.79M | -3.66M |
| Income Before Tax | -8.46M | -6.40M | -4.34M | -4.43M | -4.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.46 | -6.40 | -4.34 | -4.43 | -4.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -710.40K | -1.42M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.46M | -6.40M | -4.34M | -5.14M | -5.94M |
| EBIT | -6.85M | -5.38M | -3.92M | -3.79M | -3.66M |
| EBITDA | -- | -- | -- | -1.83M | -3.66M |
| EPS Basic | -3.25 | -16.83 | -30.42 | -43.52 | -56.63 |
| Normalized Basic EPS | -2.03 | -1.67 | -1.32 | -7.44 | -13.56 |
| EPS Diluted | -3.25 | -16.83 | -30.42 | -43.52 | -56.63 |
| Normalized Diluted EPS | -2.03 | -1.67 | -1.32 | -7.44 | -13.56 |
| Average Basic Shares Outstanding | 11.33M | 8.22M | 4.61M | 2.76M | 911.30K |
| Average Diluted Shares Outstanding | 11.33M | 8.22M | 4.82M | 2.97M | 1.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |